Novo Nordisk A/S Release: New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) Is as Effective as Glargine Over a 24-Hour Period in Subjects With Type 2 Diabetes

SAN FRANCISCO, CA--(Marketwire - June 08, 2008) - A head-to-head study announced today at the American Diabetes Association (ADA) meeting demonstrated that Levemir® (insulin detemir [rDNA origin] injection) can be used once-daily and had a comparable blood glucose response to insulin glargine over a 24-hour period in patients with type 2 diabetes.